Get the Stockscreener App
12.24
4.44%
0.52
Ocular Therapeutix Inc stock is traded at $12.24, with a volume of 3.28M.
It is up +4.44% in the last 24 hours and up +3.99% over the past month.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
See More
Previous Close:
$11.72
Open:
$11.67
24h Volume:
3.28M
Relative Volume:
1.21
Market Cap:
$2.61B
Revenue:
$61.10M
Net Income/Loss:
$-138.36M
P/E Ratio:
-9.0667
EPS:
-1.35
Net Cash Flow:
$-90.59M
1W Performance:
+8.32%
1M Performance:
+3.99%
6M Performance:
+67.67%
1Y Performance:
+43.66%
1-Day Range:
$11.63
$12.36
1-Week Range:
$11.08
$12.55
52-Week Range:
$5.80
$13.85
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Name
Ocular Therapeutix Inc
Sector
Industry
Phone
781-357-4000
Address
15 CROSBY DRIVE, BEDFORD, MA
Compare OCUL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
12.24 | 2.50B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-15-25 | Initiated | Chardan Capital Markets | Buy |
| Apr-08-25 | Initiated | William Blair | Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Mar-11-25 | Initiated | Needham | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-20-24 | Upgrade | TD Cowen | Hold → Buy |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Feb-09-24 | Initiated | BofA Securities | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Aug-10-22 | Resumed | Berenberg | Buy |
| Aug-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-28-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Nov-13-20 | Reiterated | Raymond James | Strong Buy |
| Aug-10-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-03-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| May-21-19 | Downgrade | Cowen | Outperform → Market Perform |
| May-21-19 | Reiterated | H.C. Wainwright | Buy |
| May-21-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-03-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-18 | Initiated | Raymond James | Strong Buy |
| Sep-07-18 | Initiated | Piper Jaffray | Overweight |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Jul-26-17 | Initiated | H.C. Wainwright | Buy |
| Jul-12-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jun-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-10-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | RBC Capital Mkts | Outperform |
| Aug-11-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-17-16 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-23-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-13-15 | Initiated | Morgan Stanley | Overweight |
View All
Ocular Therapeutix Inc Stock (OCUL) Latest News
Behavioral Patterns of OCUL and Institutional Flows - news.stocktradersdaily.com
Why Ocular Therapeutix Inc. (0OT) stock remains stableIndex Update & Reliable Intraday Trade Plans - newser.com
Will Ocular Therapeutix Inc. stock see PE expansionWeekly Profit Summary & Weekly Top Performers Watchlists - newser.com
Is Ocular Therapeutix Inc. stock a safe haven assetJuly 2025 WrapUp & Verified Chart Pattern Trade Signals - newser.com
Will Ocular Therapeutix Inc. stock pay special dividendsWeekly Investment Recap & Entry Point Confirmation Signals - newser.com
Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 82.48%: Read This Before Placing a Bet - sharewise.com
Published on: 2025-11-20 06:23:38 - newser.com
Why analysts recommend Ocular Therapeutix Inc. (0OT) stockInflation Watch & Technical Pattern Alert System - newser.com
Why Ocular Therapeutix Inc. (0OT) stock stays on top picksRate Hike & High Return Stock Watch Alerts - newser.com
Is this a good reentry point in Ocular Therapeutix Inc.2025 Trade Ideas & Weekly Top Performers Watchlists - newser.com
How Ocular Therapeutix Inc. (0OT) stock behaves in tightening cyclesWeekly Profit Analysis & AI Enhanced Trading Alerts - newser.com
Is Ocular Therapeutix Inc. stock near bottom after declineJuly 2025 Institutional & Intraday High Probability Alerts - newser.com
Will Ocular Therapeutix Inc. stock see insider buyingSell Signal & Long-Term Safe Investment Ideas - newser.com
Published on: 2025-11-19 13:52:30 - newser.com
Why Ocular Therapeutix Inc. (0OT) stock could be top winner2025 Bull vs Bear & Weekly Breakout Watchlists - newser.com
Will Ocular Therapeutix Inc. stock deliver consistent dividendsQuarterly Trade Review & Real-Time Volume Surge Alerts - newser.com
Comparing Ocular Therapeutix Inc. in custom built stock radarsStop Loss & Growth Focused Stock Pick Reports - newser.com
Will Ocular Therapeutix Inc. stock go up soonMarket Trend Summary & Detailed Earnings Play Alerts - newser.com
Ocular Therapeutix (OCUL) Soars 5% Ahead of Health Conferences - MSN
Why Ocular Therapeutix Inc. stock is recommended by analystsQuarterly Profit Report & Expert Approved Momentum Ideas - newser.com
Is Ocular Therapeutix Inc. stock a buy in volatile markets2025 Key Lessons & Fast Gain Stock Tips - newser.com
Ocular Therapeutix Inc Stock (OCUL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):